Reduced membrane lipids in the cortex of alzheimer's disease transgenic mice

Neurochemical Research

Volumn 34, Issue 1, 2009, Pages 102-108

  Yao, Jeffrey K ^a,b,c   Wengenack, Thomas M ^d,e   Curran, Geoffry L ^d,e   Poduslo, Joseph F ^d,e  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d Mayo Clinic   (United States)

^e MAYO GRADUATE SCHOOL   (United States)

Author keywords

Alzheimer's disease; Cortex; Double transgenic mice; Lipids; Polyunsaturated fatty acids

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; AMYLOID PROTEIN; ARACHIDONIC ACID; CHOLESTEROL; DOCOSAHEXAENOIC ACID; FATTY ACID; GALACTOSYLCERAMIDE; MEMBRANE LIPID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLSERINE; PHOSPHOLIPID; POLYMER; PRESENILIN 1;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; C57BL 6 MOUSE; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIGHT SCATTERING; MOUSE; NERVE CELL MEMBRANE; NEUROTOXICITY; NONHUMAN; PRECURSOR; PRIORITY JOURNAL; TISSUE LEVEL; TRANSGENIC MOUSE; WILD TYPE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; FATTY ACIDS; MEMBRANE LIPIDS; MICE; MICE, TRANSGENIC; PRESENILIN-1;

MUS; MUS MUSCULUS;

EID: 58149465620     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-008-9673-1     Document Type: Article

References (40)

1. R Katzman T Saitoh 1991 Advances in Alzheimer's disease FASEB J 5 278 286
2. TE Golde CB Eckman S Younkin 2000 Biochemical detection of Aβ isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease Biochim Biophys Acta 1502 172 187
3. DJ Selkoe 2001 Alzheimer's Disease: genes, proteins, and therapy Psychol Rev 81 741 766
4. DJ Selkoe 1996 Amyloid β-protein and the genetics of Alzheimer's disease J Biol Chem 271 18295 18298
5. JL Price JC Morris 1999 Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease Ann Neurol 45 358 368
6. R Kayed E Head JL Thompson 2003 Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis Science 300 486 489
7. JK Blusztajn IL Gonzalez-Coviella M Logue 1990 Levels of phospholipid catabolic intermediates, glycerophosphocholine and glycerophosphoethanol-amine, are elevated in brains of Alzheimer's disease but not of Down's syndrome patients Brain Res 536 240 244
8. RM Nitsch JK Blusztajn AG Pittas 1992 Evidence for a membrane defect in Alzheimer disease brain Proc Natl Acad Sci 89 1671 1675
9. M Söderberg C Edlund K Kristensson 1991 Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease Lipids 26 421 425
10. K Hsiao P Chapman S Nilsen 1996 Coorelative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice Science 274 99 102
11. YM Kuo TG Beach LI Sue 2001 The evolution of A beta peptide burden in the APP23 transgenic mice: implications for A beta deposition in Alzheimer disease Mol Med 7 609 618
12. L Holcomb MN Gordon E McGowan 1998 Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes Nature Med 4 97 100
13. YM Kuo TA Kokjohn TG Beach 2001 Comparative analysis of amyloid-β chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains J Biol Chem 276 12991 12998
14. TM Wengenack SL Whelan GL Curran 2000 Quantitative histological analysis of amyloid disposition in Alzheimer's double transgenic mouse brain Neuroscience 101 939 944
15. JF Poduslo GL Curran TM Wengenack 2001 Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease Neurobiol Dis 8 555 567
16. L Svennerholm K Bostrom CG Helander 1991 Membrane lipids in the aging human brain J Neurochem 56 2051 2059
17. JK Yao S Leonard R Reddy 2000 Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients Schizophr Res 42 7 17
18. K Ichihara A Shibahara K Yamamoto 1996 An improved method for rapid analysis of the fatty acids of glycerolipids Lipids 31 535 539
19. 31P nuclear magnetic resonance study of the brain in Alzheimer's disease J Neuropathol Exp Neurol 47 235 248
20. 2 in the central nervous system: implications for neurodegenerative diseases J Lipid Res 45 205 213
21. 2-generated lipid mediators in the brain: the good, the bad, and the ugly Neuroscientist 12 245 260
22. 2 mediate amyloid-β peptide-induced mitochondrial dysfunction J Neurosci 26 11111 11119
23. WB Grant 1997 Dietary links to Alzheimer's disease Alzheimer's Dis Rev 2 42 55
24. S Kalmijn LJ Launer A Ott JC Witteman A Hofman MM Breteler 1997 Dietary fat intake and the risk of incident dementia in the Rotterdam Study Ann Neurol 42 776 782
25. MA Smith GJ Petot G Perry 1999 Diet and oxidative stress: a novel synthesis of epidemiological data on Alzheimer's disease J Alzheimers Dis 1 203 206
26. F Calon GP Lim F Yang T Morihara B Teter O Ubeda P Rostaing A Triller N Salem Jr KH Ashe 2004 Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model Neuron 43 633 645
27. MC Morris DA Evans JL Bienias 2003 Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease Arch Neurol 60 940 946
28. GP Lim F de'ric Calon T Morihara 2005 A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model Neurolbiol Dis 25 3032 3040
29. C Sahlin FE Pettersson LNG Nilsson L Lannfelt AS Johansson 2007 Docosa-hexaenoic acid stimulates non-amyloidogenic APP processing resulting in reduced Aβ levels in cellular models of Alzheimer's disease Eur J Neurosci 26 882 889
30. DJ Kyle E Schaefer G Patton 1999 Low serum docosahexaenoic acid is a significant risk factor for Alzheimer's dementia Lipids 34 Suppl S245
31. E Soyland T Lea B Sandstand A Drevon 1994 Dietary supplementation with very long-chain n-3 fatty acids in man decreases expression of the interleukin-2 receptor (CD25) on mitogen-stimulated lymphocytes from patients with infammatory skin disease Eur J Clin Invest 24 236 242
32. T Tashiro H Yamamori K Takagi N Hayashi K Furukawa N Nakajima 1998 n-3 Versus n-6 polyunsaturated fatty acids in critical illness Nutrition 14 551 553
33. J McLaurin A Chakrabartty 1996 Membrane disruption by Alzheimer β-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Implications for neurotoxicity J Biol Chem 271 26482 26489
34. RP Mason JD Estermyer JF Kelly 1996 Alzheimer's disease amyloid beta peptide 25-35 is localized in the membrane hydrocarbon core: X-ray diffraction analysis Biochem Biophys Res Commun 222 78 82
35. SR Ji Y Wu S Sui 2002 Cholesterol is an important factor affecting the membrane insertion of β-amyloid peptide (aβ1-40), which may potentially inhibit the fibril formation J Biol Chem 277 6273 6279
36. RP Friedland 2002 Lipid metabolism, epidemiology, and the mechanisms of Alzheimer's disease Ann N Y Acad Sci 977 387 390
37. DH Small D Maksel ML Kerr J Ng X Hou C Chu H Mehrani S Unabia MF Azari R Loiacono MI Aguilar M Chebib 2007 The β-amyloid protein of Alzheimer's disease binds to membrane lipids but does not bind to the α7 nicotinic acetylcholine receptor J Neurochem 101 1527 1538
38. WG Wood GP Eckert U Igbavboa 2003 Amyloid beta-protein interactions with membranes and cholesterol: causes or casualties of Alzheimer's disease Biochim Biophys Acta 1610 281 290
39. GS Roth JA Joseph RP Mason 1995 Membrane alterations as cause of impaired signal transduction in Alzheimer's disease and aging Trends Neurosci 18 203 206
40. MOW Grimm HS Grimm AJ Patzold 2005 Regulation of cholesterol and sphingomyelin metabolism by amyloid-β and presenilin Nature Cell Biol 7 1118 1123